fda glp-1 warning letters september 2025 news takes aim at Hims & Hers, weight loss drugs in ad blitz FDA Issues 30 Warning Letters

Classic parameters from peer-reviewed literature

The FDA has issued warnings regarding certain compounded semaglutide and tirzepatide products, citing concerns related to purity, dosing accuracy, and contamination

In the SURMOUNT-1 trial, which evaluated tirzepatide for chronic weight management in adults without diabetes, approximately 67% of participants were women

NES-Venus-mG s , NES-Venus-mG q , and Venus-KRAS (Wan et al., 2018) were kind gifts from Mohammed Ayoub (Khalifa University, Abu Dhabi, United Arab Emirates)

Alternative Medicine Review, 16 (4), 355364

In conclusion, the findings from Adamou et al.s meta-analysis underscore the potential of GLP-1 RAs as a promising tool in stroke prevention, particularly for patients with diabetes and obesity